JUULpods
Commercial- Indications
- Nicotine delivery, Smoking cessation
Company intelligence / Profile preview
Juul Labs commercializes electronic nicotine delivery systems ("e-cigarettes") designed to provide an alternative to combustible cigarettes. The company's products have been widely adopted by adult smokers but have also faced regulatory scrutiny and lawsuits due to youth usage and marketing practices. As of 2025, underage use of JUUL products has reportedly dropped significantly since its peak in 2019[8].
The FDA issued a Marketing Denial Order for JUUL products in June 2022; this was subsequently blocked by court order and the company continues to operate while navigating ongoing regulatory challenges[1].
No clinical trial results are available as the product category does not require traditional drug development trials.
The company's market share has declined from its peak but it remains one of the most recognized e-cigarette brands in the U.S.[1]
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Juul Labs.